{
    "nctId": "NCT00635245",
    "briefTitle": "CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery",
    "officialTitle": "A Phase 1 Pharmacodynamic Study Of CP-751,871 As Neoadjuvant Treatment For Early Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Tumor total choline (tCho) changes determined by magnetic resonance spectroscopy",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed early operable adenocarcinoma of the breast\n* No evidence of invasive lobular breast disease\n* Measurable disease, defined as at least 1 lesion \u2265 2 cm by MRI\n* Measurable levels of total choline according to institutional criteria by magnetic resonance spectroscopy\n* Must have available or scheduled core breast biopsy procedure\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* ECOG performance status 0-1\n* Platelet count \u2265 100,000/mm\\^\u00b3\n* Neutrophil count \u2265 1,500/mm\u00b3\n* Creatinine \\< 1.5 times upper limit of normal (ULN)\n* Bilirubin \\< 1.5 times ULN\n* ALT and AST \\< 2.5 times ULN\n* Fertile patients must use adequate barrier method contraception during and for at least 150 days after completion of study treatment\n* Ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures\n* No known hypersensitivity to monoclonal antibodies\n* No prior or active malignancies other than curatively treated in situ carcinoma of the cervix, uterus, or basal cell or squamous cell carcinoma of the skin\n* No serious uncontrolled medical disorder or active infection that would impair the ability to receive study treatment\n* No significant active cardiac disease including any of the following:\n\n  * Uncontrolled high blood pressure (i.e., systolic blood pressure \\[BP\\] \\> 160 mm Hg and diastolic BP \\> 95 mm Hg)\n  * Unstable angina\n  * Deep venous thrombosis\n  * Pulmonary embolism\n  * Cerebrovascular attack\n  * Valvular disease\n  * Congestive heart failure\n  * Myocardial infarction with the past 6 months\n  * Serious cardiac arrhythmias\n* No dementia or significantly altered mental status that would limit the understanding or rendering of informed consent and compliance with study requirements\n\nPRIOR CONCURRENT THERAPY:\n\n* More than 4 weeks since prior surgery and recovered\n* More than 2 weeks since high-dose corticosteroid therapy (i.e., \u2265 100 mg prednisone per day or \\> 40 mg dexamethasone per day)\n* No prior anti-IGF-1R based investigational therapy\n* No prior systemic therapy for primary disease\n* No concurrent chronic systemic high-dose immunosuppressive steroid therapy\n\n  * Low-dose steroids for nausea and vomiting control allowed\n  * Topical corticosteroid applications, inhaled sprays, eye drops or local injections (e.g., intraocular) allowed\n* No concurrent other anticancer drugs or therapy",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}